Extraordinary science deserves extraordinary commitment
Assemble Ventures helps early-stage life sciences and health tech companies engage with patient communities to de-risk the development and delivery processes and produce better outcomes for people, business, and scientific advancement. We offer flexible partnership structures that often include equity as a meaningful portion of our compensation.
Expert engagement for early-stage companies
You've probably been told to "engage early with patient communities." We have found that life sciences founders often don't know how to work with patients in a rigorous, timely, and cost-effective way. Early-stage companies deserve experienced partners who will help them engage with patients at key trajectory-setting moments.
Patient-focused strategic partner for your portfolio
We work with portfolio companies as an accelerant at the moments where rigorous patient engagement can materially improve their risk profile. That might mean helping companies define endpoints that matter to patients, regulators, and payors, or design a trial people can actually join. We bring the rigor of large pharma programs in models built for early-stage companies. Your companies get a senior team that moves fast and is invested in their success.